Roberts JD - Search Results

1

Nitric oxide modulates lymphocyte proliferation but not secretion of IL-2.

Huot AE, Moore AL, Roberts JD, Hacker MP. Huot AE, et al. Among authors: roberts jd. Immunol Invest. 1993 Jun;22(4):319-27. doi: 10.3109/08820139309063411. Immunol Invest. 1993. PMID: 7689536

2

Increased systemic, but not regional, neopterin production following intraperitoneal administration of interleukin-2 and lack of effect of pterins upon the lymphokine-activated killer cell phenomenon.

Roberts JD, Bigelow JC, Moore AL, Belinson JL, Stewart JA, Hacker MP. Roberts JD, et al. J Immunother Emphasis Tumor Immunol. 1994 Jan;15(1):53-8. doi: 10.1097/00002371-199401000-00007. J Immunother Emphasis Tumor Immunol. 1994. PMID: 8110731

3

Shikimic acid complexes of platinum. Preparation, reactivity, and antitumor activity of (R,R-1,2-diaminocyclohexane) bis(shikimato) platinum(II). Evidence for a novel rearrangement involving platinum-carbon bond formation.

Farrell N, Roberts JD, Hacker MP. Farrell N, et al. Among authors: roberts jd. J Inorg Biochem. 1991 Jun;42(4):237-46. doi: 10.1016/0162-0134(91)84038-b. J Inorg Biochem. 1991. PMID: 1880505

4

Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.

Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF. Stewart JA, et al. Among authors: roberts jd. Cancer Res. 1990 Oct 1;50(19):6302-10. Cancer Res. 1990. PMID: 2205379 Clinical Trial.

5

Metabolism of tiazofurin by human erythrocytes and mononuclear blood cells in vitro.

Roberts JD, Tong WP, Hartshorn JN, Hacker MP. Roberts JD, et al. Cancer Lett. 1986 Aug;32(2):193-7. doi: 10.1016/0304-3835(86)90119-9. Cancer Lett. 1986. PMID: 3756845

6

Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice.

Roberts JD, Hacker MP, Newman RA, McCormack JJ, Krakoff IH. Roberts JD, et al. Invest New Drugs. 1984;2(2):215-20. doi: 10.1007/BF00232354. Invest New Drugs. 1984. PMID: 6469517

7

Regional fibrosis after intraperitoneal administration of mafosfamide.

Roberts JD, Newman RA, Kimberly PJ, Hacker MP. Roberts JD, et al. Invest New Drugs. 1986;4(1):61-5. doi: 10.1007/BF00172019. Invest New Drugs. 1986. PMID: 2939038

8

Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action.

Farrell N, Kelland LR, Roberts JD, Van Beusichem M. Farrell N, et al. Among authors: roberts jd. Cancer Res. 1992 Sep 15;52(18):5065-72. Cancer Res. 1992. PMID: 1516063

9

A phase I clinical trial of didemnin B.

Stewart JA, Low JB, Roberts JD, Blow A. Stewart JA, et al. Among authors: roberts jd. Cancer. 1991 Dec 15;68(12):2550-4. doi: 10.1002/1097-0142(19911215)68:12<2550::aid-cncr2820681203>3.0.co;2-q. Cancer. 1991. PMID: 1933801 Clinical Trial.

10

Effect of obesity on plasma insulin-like growth factor-I in cancer patients.

Colletti RB, Copeland KC, Devlin JT, Roberts JD, McAuliffe TL. Colletti RB, et al. Among authors: roberts jd. Int J Obes. 1991 Aug;15(8):523-7. Int J Obes. 1991. PMID: 1938095

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

642 results

Search Page

Filters